FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
FDA granted accelerated approval to trastuzumab deruxtecan-nxki (Enhertu, AstraZeneca and Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
The approval comes well in advance of the May 30, 2024, target date. Trastuzumab deruxtecan-nxki is an HER2-directed antibody drug conjugate (ADC), and this approval makes it the first tumor-agnostic approval of a HER2-directed therapy and an ADC.
“Until the approval of trastuzumab deruxtecan, patients with metastatic HER2 positive solid tumors have had limited treatment options,” Funda Meric-Bernstam, MD, chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, said in a statement. “Based on the clinically meaningful response rates seen across clinical trials, this tumor-agnostic approval means that patients may now be treated with a HER2 directed medicine.”
The approval was based on a review of 3 multicenter trials: DESTINY-PanTumor02 (NCT04482309), DESTINY-Lung01 (NCT03505710), and DESTINY-CRC02 (NCT04744831).
The review was conducted under Project Orbis, which provides a framework for concurrent submission and review of oncology drugs among international partners. FDA collaborated with Australian Therapeutic Goods Administration, the Brazilian Health Regulatory Agency, Health Canada, and Singapore’s Health Sciences Authority. Reviews at other agencies are ongoing.
This is the second time in 4 months FDA has granted approval to an ADC-based regimen far in advance of its target date. In December, enfortumab vedotin (Padcev, Astellas Pharma) plus pembrolizumab (Keytruda, Merck) was approved to treat locally advanced or metastatic bladder cancer.
Meric-Bernstam presented data from DESTINY-PanTumor02 in June 2023 during the annual meeting of the American Society of Clinical Oncology (ASCO).1 Results from the phase 2 trial showed trastuzumab deruxtecan could be an option for patients with rarer cancers expressing HER2; these patients often have unmet need, as their numbers are insufficient to make up a tumor-specific study.
“For these patients there are no approved or targeted treatments, and often the disease is refractory to standard-of-care therapies,” Meric-Bernstam said during a press conference at ASCO.
Trastuzumab deruxtecan brought strong responses in endometrial, cervical, ovarian, and urothelial cancers after a median of 9.7 months of follow-up, particularly for patients with HER2+ tumors with immunohistochemistry (IHC) scores of 3+. Only pancreatic tumors with HER2+ expression had poor responses.
“These results advance our clinical understanding of HER2 expression, reaffirm HER2 as an actionable biomarker across a broad range of tumor types, and show that trastuzumab deruxtecan could potentially provide a new treatment option for patients with advanced disease across these tumors, especially in patients with HER2 IHC 3+ or 2+ expression,” she said.
Reference
Meric-Bernstam F, Makker V, Oaknin A. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. J Clin Oncol. 2023;41(suppl 17):abstract LBA3000. doi:10.1200/JCO.2023.41.17_suppl.LBA3000
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen